ECSP11011437A - COMPOUNDS AND METHODS FOR THE MODULATION OF KINASES AND INDICATIONS OF THE SAME - Google Patents
COMPOUNDS AND METHODS FOR THE MODULATION OF KINASES AND INDICATIONS OF THE SAMEInfo
- Publication number
- ECSP11011437A ECSP11011437A EC2011011437A ECSP11011437A ECSP11011437A EC SP11011437 A ECSP11011437 A EC SP11011437A EC 2011011437 A EC2011011437 A EC 2011011437A EC SP11011437 A ECSP11011437 A EC SP11011437A EC SP11011437 A ECSP11011437 A EC SP11011437A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- methods
- kinases
- indications
- modulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen compuestos y sales de los mismos, formulaciones de los mismos, conjugados de los mismos, derivados de los mismos, formas de los mismos y usos de los mismos. En algunos aspectos y formas de realización, los compuestos descriptos o sales de los mismos, formulaciones de los mismos, conjugados de los mismos, derivados de los mismos y formas de los mismos son activos en cada una de las proteína quinasas BRaf y c-Raf-1, y también pueden ser activos en cualquiera, o ambas, de las proteínas quinasas A-Raf y B-Raf V600E. También se describen métodos de uso de los mismos para tratar enfermedades y condiciones, incluyendo melanoma, cáncer colorrectal, cáncer de tiroides, cáncer ovárico y cáncer del tracto biliar.Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In some aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof and forms thereof are active in each of the BRaf and c-Raf protein kinases. -1, and can also be active in either, or both, of the protein kinases A-Raf and B-Raf V600E. Methods of using them to treat diseases and conditions, including melanoma, colorectal cancer, thyroid cancer, ovarian cancer and biliary tract cancer, are also described.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17605409P | 2009-05-06 | 2009-05-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP11011437A true ECSP11011437A (en) | 2011-12-30 |
Family
ID=42236712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2011011437A ECSP11011437A (en) | 2009-05-06 | 2011-11-01 | COMPOUNDS AND METHODS FOR THE MODULATION OF KINASES AND INDICATIONS OF THE SAME |
Country Status (23)
Country | Link |
---|---|
US (3) | US8198273B2 (en) |
EP (2) | EP2427433A1 (en) |
JP (2) | JP2012526127A (en) |
KR (1) | KR20140014386A (en) |
CN (1) | CN102459262A (en) |
AR (1) | AR076749A1 (en) |
AU (1) | AU2010246005A1 (en) |
BR (1) | BRPI1013843A2 (en) |
CA (1) | CA2759997A1 (en) |
CL (1) | CL2011002739A1 (en) |
CR (1) | CR20110562A (en) |
EC (1) | ECSP11011437A (en) |
IL (1) | IL215908A0 (en) |
MA (1) | MA34042B1 (en) |
MX (1) | MX2011011737A (en) |
NI (1) | NI201100189A (en) |
NO (1) | NO20111508A1 (en) |
PE (1) | PE20120518A1 (en) |
RU (1) | RU2011149485A (en) |
SG (1) | SG175810A1 (en) |
TW (1) | TW201041888A (en) |
WO (2) | WO2010129567A1 (en) |
ZA (1) | ZA201108124B (en) |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1893612B1 (en) * | 2005-06-22 | 2011-08-03 | Plexxikon, Inc. | Pyrrolo [2, 3-b]pyridine derivatives as protein kinase inhibitors |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
SG183036A1 (en) | 2007-07-17 | 2012-08-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
PL2414356T3 (en) | 2009-04-03 | 2016-02-29 | Hoffmann La Roche | Propane-i-sulfonic acid {3-[5-(4-chloro-phenyl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
NZ629615A (en) | 2009-11-06 | 2016-01-29 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
RU2012125070A (en) * | 2009-11-18 | 2013-12-27 | Плексксикон, Инк. | COMPOUNDS AND METHODS OF KINASE MODULATION AND INDICATIONS FOR THEIR APPLICATION |
MX2012007429A (en) * | 2009-12-23 | 2012-07-23 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor. |
TWI619713B (en) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | Compounds and methods for kinase modulation, and indications therefor |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
US20140005160A1 (en) * | 2010-12-01 | 2014-01-02 | Hooshmand SHESHBARADARAN | Method for Treating Refractory Cancer |
WO2012106559A1 (en) * | 2011-02-02 | 2012-08-09 | Translational Genomics Research Institute | Biomarkers and methods of use thereof |
US8889684B2 (en) * | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
MA34948B1 (en) * | 2011-02-07 | 2014-03-01 | Plexxikon Inc | COMPOUNDS AND METHODS FOR MODULATING KINASE, AND INDICATIONS THEREOF |
TWI558702B (en) * | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | Solid forms of a pharmaceutically active substance |
CA2828940C (en) | 2011-03-10 | 2024-04-16 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
WO2012138809A1 (en) * | 2011-04-05 | 2012-10-11 | Dawei Zhang | Heterocyclic compounds as kinase inhibitors |
WO2012158957A2 (en) | 2011-05-17 | 2012-11-22 | Plexxikon Inc. | Kinase modulation and indications therefor |
CN107245056A (en) | 2011-08-26 | 2017-10-13 | 润新生物公司 | Chemical entities, composition and method |
CN102993199A (en) * | 2011-09-09 | 2013-03-27 | 山东轩竹医药科技有限公司 | Heterocycle substituted pyrido-pyrrole kinase inhibitor |
EP3332785B1 (en) | 2011-09-14 | 2020-05-06 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
EP2757885B1 (en) | 2011-09-21 | 2017-03-15 | Neupharma, Inc. | Certain chemical entites, compositions, and methods |
WO2013049701A1 (en) | 2011-09-30 | 2013-04-04 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
US9670180B2 (en) | 2012-01-25 | 2017-06-06 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
JP6013029B2 (en) * | 2012-05-25 | 2016-10-25 | 千葉県 | Anticancer drug |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
US9150570B2 (en) * | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
JO3407B1 (en) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | Tetrahydropyrazolopyrimidine Compounds |
CN104470920A (en) * | 2012-07-03 | 2015-03-25 | 通益制药有限公司 | Solid state form of vemurafenib choline salt |
DE102012016908A1 (en) * | 2012-08-17 | 2014-02-20 | Aicuris Gmbh & Co. Kg | Tris (hetero) aryl-pyrazoles and their use |
TWI601725B (en) | 2012-08-27 | 2017-10-11 | 加拓科學公司 | Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use |
MX2015002887A (en) | 2012-09-06 | 2015-07-06 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor. |
WO2014047648A1 (en) | 2012-09-24 | 2014-03-27 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
CN103613591B (en) * | 2012-09-29 | 2016-04-13 | 上海科州药物研发有限公司 | As the compound and its production and use of cMet inhibitor |
US9725421B2 (en) | 2012-11-12 | 2017-08-08 | Neupharma, Inc. | Substituted quinoxalines as B-raf kinase inhibitors |
SG11201503977PA (en) * | 2012-11-20 | 2015-06-29 | Principia Biopharma Inc | Azaindole derivatives as jak3 inhibitors |
CA2895239C (en) | 2012-12-21 | 2020-10-27 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2014111496A1 (en) * | 2013-01-18 | 2014-07-24 | F. Hoffmann-La Roche Ag | 3-substituted pyrazoles and use as dlk inhibitors |
CA2900951A1 (en) | 2013-03-14 | 2014-10-02 | Ratiopharm Gmbh | Solid state forms of vemurafenib hydrochloride |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
MX2015012456A (en) | 2013-03-15 | 2016-02-03 | Plexxikon Inc | Heterocyclic compounds and uses thereof. |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
EP3004060B1 (en) | 2013-05-30 | 2019-11-27 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
WO2015075749A1 (en) * | 2013-11-22 | 2015-05-28 | Laurus Labs Private Limited | Novel processes for the preparation of vemurafenib |
CZ2013943A3 (en) | 2013-11-27 | 2015-06-03 | Zentiva, K.S. | Vemurafenib crystalline forms |
WO2015134536A1 (en) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
JO3512B1 (en) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | Quinoxaline derivatives useful as fgfr kinase modulators |
AU2015238301B2 (en) | 2014-03-26 | 2020-06-25 | Astex Therapeutics Ltd | Combinations |
KR102479696B1 (en) | 2014-03-26 | 2022-12-22 | 아스텍스 테라퓨틱스 리미티드 | Combinations of an fgfr inhibitor and an igf1r inhibitor |
NO2714752T3 (en) * | 2014-05-08 | 2018-04-21 | ||
US9856259B2 (en) | 2014-09-15 | 2018-01-02 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
JOP20200201A1 (en) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
CZ2015250A3 (en) | 2015-04-14 | 2016-10-26 | Zentiva, K.S. | Vemurafenib amorphous forms |
US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
AU2016328619B2 (en) | 2015-09-21 | 2020-07-16 | Opna Bio SA | Heterocyclic compounds and uses thereof |
JP6898919B2 (en) | 2015-09-23 | 2021-07-07 | ヤンセン ファーマシューティカ エヌ.ベー. | New compound |
HUE057090T2 (en) | 2015-09-23 | 2022-04-28 | Janssen Pharmaceutica Nv | Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer |
WO2017100201A1 (en) | 2015-12-07 | 2017-06-15 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2017161045A1 (en) | 2016-03-16 | 2017-09-21 | Plexxikon Inc. | Compounds and methods for kinase modulation and indications therefore |
US10195188B2 (en) | 2016-06-13 | 2019-02-05 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
KR20240110902A (en) * | 2016-06-13 | 2024-07-16 | 케모센트릭스, 인크. | Methods of treating pancreatic cancer |
CN107722013B (en) * | 2016-08-11 | 2021-01-12 | 中国科学院上海药物研究所 | Deazapurine compounds, pharmaceutical compositions, preparation method and uses thereof |
TW201815766A (en) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | Compounds and methods for IDO and TDO modulation, and indications therefor |
EP4134080A1 (en) | 2016-11-23 | 2023-02-15 | ChemoCentryx, Inc. | Ccr2 inhibitors for use in treating renal diseases |
CA3047580A1 (en) | 2016-12-23 | 2018-07-26 | Plexxikon Inc. | Compounds and methods for cdk8 modulation and indications therefor |
BR112019014593A2 (en) | 2017-01-17 | 2020-02-18 | Heparegenix Gmbh | MKK4 INHIBITOR AND THE PHARMACEUTICALLY ACCEPTABLE OPTICAL SALES, SOLVATES AND ISOMERS OF THE SAME, COMPOUND AND THE PHARMACEUTICALLY ACCEPTABLE PHARMACEUTICALLY ACCEPTABLE INITIATIVE KNOWLEDGE PROTECTION IN THE PROTEIN OF THE KNOWLEDGE |
JP2020511467A (en) | 2017-03-20 | 2020-04-16 | プレキシコン インコーポレーテッドPlexxikon Inc. | 4- (1- (1,1-di (pyridin-2-yl) ethyl) -6- (3,5-dimethylisoxazol-4-yl) -1H-pyrrolo [3,2- that inhibits the bromodomain b] Pyridin-3-yl) benzoic acid crystalline form |
WO2018226846A1 (en) | 2017-06-07 | 2018-12-13 | Plexxikon Inc. | Compounds and methods for kinase modulation |
WO2019023198A1 (en) | 2017-07-25 | 2019-01-31 | Plexxikon Inc. | Formulations of a compound modulating kinases |
CA3078809A1 (en) | 2017-10-11 | 2019-04-18 | Chemocentryx, Inc. | Treatment of focal segmental glomerulosclerosis with ccr2 antagonists |
CA3079029A1 (en) | 2017-10-13 | 2019-04-18 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
AU2018354423A1 (en) | 2017-10-27 | 2020-05-14 | Plexxikon Inc. | Formulations of a compound modulating kinases |
AU2019207491A1 (en) | 2018-01-10 | 2020-07-30 | Cura Therapeutics, Llc | Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications |
EP3746437B1 (en) | 2018-01-31 | 2024-08-21 | HepaRegeniX GmbH | Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
EP3768666A1 (en) | 2018-03-20 | 2021-01-27 | Plexxikon Inc. | Compounds and methods for ido and tdo modulation, and indications therefor |
EP3810139A1 (en) | 2018-06-21 | 2021-04-28 | HepaRegeniX GmbH | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
US11912701B2 (en) | 2018-07-16 | 2024-02-27 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2277551E (en) * | 2002-09-06 | 2013-08-22 | Cerulean Pharma Inc | Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto |
EP1893612B1 (en) | 2005-06-22 | 2011-08-03 | Plexxikon, Inc. | Pyrrolo [2, 3-b]pyridine derivatives as protein kinase inhibitors |
DE102005034406A1 (en) | 2005-07-22 | 2007-02-01 | Ratiopharm Gmbh | New salts of rosiglitazone |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
GB0624084D0 (en) | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
PE20121126A1 (en) * | 2006-12-21 | 2012-08-24 | Plexxikon Inc | PIRROLO [2,3-B] PYRIDINES COMPOUNDS AS KINASE MODULATORS |
WO2008079909A1 (en) * | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
SG183036A1 (en) * | 2007-07-17 | 2012-08-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
-
2010
- 2010-04-30 TW TW099113997A patent/TW201041888A/en unknown
- 2010-05-04 BR BRPI1013843A patent/BRPI1013843A2/en not_active IP Right Cessation
- 2010-05-04 WO PCT/US2010/033571 patent/WO2010129567A1/en active Application Filing
- 2010-05-04 MA MA34424A patent/MA34042B1/en unknown
- 2010-05-04 CN CN2010800305090A patent/CN102459262A/en active Pending
- 2010-05-04 AU AU2010246005A patent/AU2010246005A1/en not_active Abandoned
- 2010-05-04 EP EP10717980A patent/EP2427433A1/en not_active Withdrawn
- 2010-05-04 WO PCT/US2010/033576 patent/WO2010129570A1/en active Application Filing
- 2010-05-04 MX MX2011011737A patent/MX2011011737A/en not_active Application Discontinuation
- 2010-05-04 US US12/773,798 patent/US8198273B2/en active Active
- 2010-05-04 SG SG2011078979A patent/SG175810A1/en unknown
- 2010-05-04 PE PE2011001867A patent/PE20120518A1/en not_active Application Discontinuation
- 2010-05-04 KR KR1020117029018A patent/KR20140014386A/en not_active Application Discontinuation
- 2010-05-04 EP EP10717408A patent/EP2427462A1/en not_active Withdrawn
- 2010-05-04 CA CA2759997A patent/CA2759997A1/en not_active Abandoned
- 2010-05-04 US US13/318,760 patent/US20120122860A1/en not_active Abandoned
- 2010-05-04 JP JP2012509906A patent/JP2012526127A/en active Pending
- 2010-05-04 RU RU2011149485/02A patent/RU2011149485A/en not_active Application Discontinuation
- 2010-05-04 JP JP2012509907A patent/JP2012526128A/en active Pending
- 2010-05-05 AR ARP100101517A patent/AR076749A1/en not_active Application Discontinuation
-
2011
- 2011-10-25 IL IL215908A patent/IL215908A0/en unknown
- 2011-10-26 CR CR20110562A patent/CR20110562A/en unknown
- 2011-11-01 EC EC2011011437A patent/ECSP11011437A/en unknown
- 2011-11-03 CL CL2011002739A patent/CL2011002739A1/en unknown
- 2011-11-03 NI NI201100189A patent/NI201100189A/en unknown
- 2011-11-03 NO NO20111508A patent/NO20111508A1/en not_active Application Discontinuation
- 2011-11-04 ZA ZA2011/08124A patent/ZA201108124B/en unknown
-
2012
- 2012-06-07 US US13/491,480 patent/US20120245174A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2010129570A1 (en) | 2010-11-11 |
EP2427462A1 (en) | 2012-03-14 |
WO2010129567A1 (en) | 2010-11-11 |
MA34042B1 (en) | 2013-03-05 |
IL215908A0 (en) | 2012-01-31 |
US20120245174A1 (en) | 2012-09-27 |
KR20140014386A (en) | 2014-02-06 |
SG175810A1 (en) | 2011-12-29 |
AU2010246005A1 (en) | 2011-12-01 |
US8198273B2 (en) | 2012-06-12 |
US20100286142A1 (en) | 2010-11-11 |
NO20111508A1 (en) | 2011-12-02 |
CA2759997A1 (en) | 2010-11-11 |
CN102459262A (en) | 2012-05-16 |
EP2427433A1 (en) | 2012-03-14 |
BRPI1013843A2 (en) | 2016-04-12 |
JP2012526127A (en) | 2012-10-25 |
NI201100189A (en) | 2012-01-11 |
JP2012526128A (en) | 2012-10-25 |
CL2011002739A1 (en) | 2012-04-09 |
US20120122860A1 (en) | 2012-05-17 |
TW201041888A (en) | 2010-12-01 |
AR076749A1 (en) | 2011-07-06 |
RU2011149485A (en) | 2013-06-20 |
PE20120518A1 (en) | 2012-05-24 |
ZA201108124B (en) | 2014-04-30 |
MX2011011737A (en) | 2011-12-08 |
CR20110562A (en) | 2012-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP11011437A (en) | COMPOUNDS AND METHODS FOR THE MODULATION OF KINASES AND INDICATIONS OF THE SAME | |
UY31829A (en) | COMPOUNDS AND METHODS FOR MODULATION OF KINASES, AND INDICATIONS FOR IT | |
NI201100168A (en) | PYRROLO [2,3-B] PYRIDINE DERIVATIVES FOR THE INHIBITION OF RAF KINASES | |
CO6551689A2 (en) | COMPOUNDS AND METHODS FOR THE MODULATION OF KINASES, AND INDICATORS FOR IT | |
CR10734A (en) | ANTIBODIES AND IMMUNOCATE PLAYERS AND THEIR USES | |
CL2019000334A1 (en) | New antibody conjugates and uses thereof (divisional application 201502357) | |
CR20120536A (en) | COMPOUNDS AND METHODS FOR THE MODULATION OF KINASE AND INDICATIONS OF THE SAME | |
ECSP088924A (en) | ANTIBODIES AND IMMUNOCATE PLAYERS AND THEIR USES | |
CL2012003075A1 (en) | Pharmaceutical composition in pazopanib solution, stable and for ophthalmic use; method for the preparation of said solution. | |
AR076105A1 (en) | PIRROL DERIVATIVES [2,3-B] PIRIDINE TO INHIBIT THE RAF QUINASA | |
TR201909582T4 (en) | Pyrimido [4,5-b] indole derivatives and their use in the expression of hematopoietic stem cells. | |
HN2005029978A (en) | FORMULATIONS | |
BRPI0912292A2 (en) | compositions and methods for the use of cells in the treatment of cardiac tissue. | |
BRPI1013771A2 (en) | "Designed mesenchymal stem cells and method of using them to treat tumors." | |
TR201907783T4 (en) | Benzosulfonamide derivatives, compositions and their use in the prevention of cancer cell metastasis. | |
RS54525B1 (en) | Means and methods for treating dlbcl | |
EA201590855A1 (en) | COMPOUNDS OF PYRROPOLYMIDININE AS KINAZ INHIBITORS | |
SV2007002813A (en) | COMPOUNDS FOR THE MODULATION OF THE ACTIVITY OF THE C-FMS AND / OR THE C-KIT AND ITS APPLICABLE USES | |
ECSP10010548A (en) | COMPOSITIONS AND METHODS OF PREPARATION AND USE OF THE SAME | |
EA201101522A1 (en) | METHODS OF TREATMENT OF DISEASES WITH THE USE OF EPIMETABOLIC SWITCH (COENZIM Q10) | |
CO6751287A2 (en) | Mycobacterial antigenic composition | |
BRPI0821489A2 (en) | Treatment of intervetebral disc degeneration using cells derived from human umbilical cord tissue | |
MX2009009117A (en) | Pyrimidine-2,4-diamine derivatives and their use as jak2 kinase inhibitors. | |
EA201001695A1 (en) | APPLICATION OF EPOTHILON D FOR THE TREATMENT OF DISEASES ASSOCIATED WITH TAU-PROTEIN | |
DK2252322T3 (en) | vaccine Compositions |